Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Shortening Buruli ulcer treatment with combination therapy targeting the respiratory chain and exploiting M. ulcerans gene decay.

Converse PJ, Almeida DV, Tyagi S, Xu J, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Apr 29. pii: AAC.00426-19. doi: 10.1128/AAC.00426-19. [Epub ahead of print]

PMID:
31036687
2.

Advancing the therapeutic potential of indoleamides for tuberculosis.

Lun S, Tasneen R, Chaira T, Stec J, Onajole OK, Yang TJ, Cooper CB, Mdluli K, Converse PJ, Nuermberger EL, Raj VS, Kozikowski A, Bishai WR.

Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00343-19. doi: 10.1128/AAC.00343-19. [Epub ahead of print]

3.

Understanding the Significance of Biochemistry in the Storage, Handling, Purification, and Sampling of Amphiphilic Mycolactone.

Kubicek-Sutherland JZ, Vu DM, Anderson AS, Sanchez TC, Converse PJ, Martí-Arbona R, Nuermberger EL, Swanson BI, Mukundan H.

Toxins (Basel). 2019 Apr 4;11(4). pii: E202. doi: 10.3390/toxins11040202.

4.

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus.

Kaushik A, Ammerman NC, Martins O, Parrish NM, Nuermberger EL.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19. doi: 10.1128/AAC.00470-19. Print 2019 Jun.

PMID:
30962331
5.

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.

Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00021-19. doi: 10.1128/AAC.00021-19. Print 2019 May.

6.

In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates.

Kaushik A, Ammerman NC, Lee J, Martins O, Kreiswirth BN, Lamichhane G, Parrish NM, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02623-18. doi: 10.1128/AAC.02623-18. Print 2019 Mar.

PMID:
30642943
7.

Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.

Almeida DV, Omansen TF, Li SY, Lee J, Grosset JH, Converse PJ, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02171-18. doi: 10.1128/AAC.02171-18. Print 2019 Mar.

PMID:
30559131
8.

High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.

Omansen TF, Almeida D, Converse PJ, Li SY, Lee J, Stienstra Y, van der Werf T, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01478-18. doi: 10.1128/AAC.01478-18. Print 2019 Feb.

PMID:
30455239
9.

Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research.

Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuermberger EL, Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M, Sassetti CM, Sizemore CF, Winthrop KL, Zelazny AM.

Am J Respir Crit Care Med. 2019 Apr 15;199(8):947-951. doi: 10.1164/rccm.201807-1273PP. No abstract available.

PMID:
30428263
10.

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.

Converse PJ, Almeida DV, Tasneen R, Saini V, Tyagi S, Ammerman NC, Li SY, Anders NM, Rudek MA, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006728. doi: 10.1371/journal.pntd.0006728. eCollection 2018 Aug.

11.

Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.

Park SW, Tasneen R, Converse PJ, Nuermberger EL.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01502-17. doi: 10.1128/AAC.01502-17. Print 2017 Nov.

12.

Preclinical Efficacy Testing of New Drug Candidates.

Nuermberger EL.

Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0034-2017. Review.

PMID:
28643624
13.

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.

Li SY, Tasneen R, Tyagi S, Soni H, Converse PJ, Mdluli K, Nuermberger EL.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00913-17. doi: 10.1128/AAC.00913-17. Print 2017 Sep.

14.

In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.

Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE, Nuermberger EL, Lamichhane G.

J Antimicrob Chemother. 2017 Aug 1;72(8):2320-2325. doi: 10.1093/jac/dkx152.

15.

Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9.

Ordonez AA, Tasneen R, Pokkali S, Xu Z, Converse PJ, Klunk MH, Mollura DJ, Nuermberger EL, Jain SK.

Dis Model Mech. 2016 Jul 1;9(7):779-88. doi: 10.1242/dmm.025643. Epub 2016 May 26.

16.

Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice.

Irwin SM, Prideaux B, Lyon ER, Zimmerman MD, Brooks EJ, Schrupp CA, Chen C, Reichlen MJ, Asay BC, Voskuil MI, Nuermberger EL, Andries K, Lyons MA, Dartois V, Lenaerts AJ.

ACS Infect Dis. 2016 Apr 8;2(4):251-267. Epub 2016 Feb 24.

17.

Extensively drug-resistant tuberculosis in a young child after travel to India.

Salazar-Austin N, Ordonez AA, Hsu AJ, Benson JE, Mahesh M, Menachery E, Razeq JH, Salfinger M, Starke JR, Milstone AM, Parrish N, Nuermberger EL, Jain SK.

Lancet Infect Dis. 2015 Dec;15(12):1485-91. doi: 10.1016/S1473-3099(15)00356-4. Epub 2015 Nov 16. Review.

18.

Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?

Lanoix JP, Chaisson RE, Nuermberger EL.

Clin Infect Dis. 2016 Feb 15;62(4):484-90. doi: 10.1093/cid/civ911. Epub 2015 Nov 1.

19.

Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.

Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):270-7. doi: 10.1128/AAC.01691-15. Print 2016 Jan.

20.

Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.

Converse PJ, Tyagi S, Xing Y, Li SY, Kishi Y, Adamson J, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2015 Jun 4;9(6):e0003823. doi: 10.1371/journal.pntd.0003823. eCollection 2015.

Supplemental Content

Loading ...
Support Center